{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:15:04Z","timestamp":1791900904027,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics Incorporated","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s13311-020-01004-3","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T18:20:47Z","timestamp":1614104447000},"page":"1127-1136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study"],"prefix":"10.1016","volume":"18","author":[{"given":"Stacy A.","family":"Rudnicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsy A.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina M.","family":"Cockroft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fady I.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Genge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Tesi-Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil T.","family":"Darras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry B.","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean K.","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Statland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali A.","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Kuntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Oskoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0086-9529","authenticated-orcid":false,"given":"John W.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-020-01004-3_bib1","doi-asserted-by":"crossref","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin 2015;33:831\u2013846.","DOI":"10.1016\/j.ncl.2015.07.004"},{"key":"10.1007\/s13311-020-01004-3_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2990.2008.00950.x","article-title":"Childhood spinal muscular atrophy induces alterations in contractile and regulatory protein isoform expressions","volume":"34","author":"Stevens","year":"2008","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1007\/s13311-020-01004-3_bib3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/NEN.0000000000000078","article-title":"Abnormalities in early markers of muscle involvement support a delay in myogenesis in spinal muscular atrophy","volume":"73","author":"Mart\u00ednez-Hern\u00e1ndez","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-020-01004-3_bib4","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00415-019-09646-w","article-title":"MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients","volume":"267","author":"Brogna","year":"2020","journal-title":"J Neurol"},{"key":"10.1007\/s13311-020-01004-3_bib5","doi-asserted-by":"crossref","unstructured":"Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377:1723\u20131732.","DOI":"10.1056\/NEJMoa1702752"},{"key":"10.1007\/s13311-020-01004-3_bib6","doi-asserted-by":"crossref","unstructured":"Mercuri E, Darras BT, Chiriboga CA, et al. Nusinersen versus sham control in later-onset spinal muscular atrophy. N Engl J Med 2018;378:625\u2013635.","DOI":"10.1056\/NEJMoa1710504"},{"key":"10.1007\/s13311-020-01004-3_bib7","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/dmcn.14027","article-title":"Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps","volume":"61","author":"Gidaro","year":"2019","journal-title":"Dev Med Child Neurol"},{"key":"10.1007\/s13311-020-01004-3_bib8","doi-asserted-by":"crossref","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology 2019;92:e2492\u2013e2506.","DOI":"10.1212\/WNL.0000000000007527"},{"key":"10.1007\/s13311-020-01004-3_bib9","doi-asserted-by":"crossref","unstructured":"Walter MC, Wenninger S, Thiele S, et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3 - a prospective observational study. J Neuromuscul Dis 2019;6:453\u2013465.","DOI":"10.3233\/JND-190416"},{"key":"10.1007\/s13311-020-01004-3_bib10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-020-01004-3_bib11","unstructured":"ZOLGENSMA\u00ae. (onasemnogene abeparvovec-xioi) suspension for intravenous infusion. U.S. Bannockburn, IL; AveXis, Inc.; 2019."},{"key":"10.1007\/s13311-020-01004-3_bib12","doi-asserted-by":"crossref","unstructured":"Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 2017;377:1713\u20131722.","DOI":"10.1056\/NEJMoa1706198"},{"key":"10.1007\/s13311-020-01004-3_bib13","unstructured":"EVRYSDI\u2122. (risdiplam) for oral solution. U.S. South San Francisco, CA; Genentech Inc.; 2020."},{"key":"10.1007\/s13311-020-01004-3_bib14","doi-asserted-by":"crossref","unstructured":"Mercuri E, Barisic N, Boespflug-Tanguy O, et al. SUNFISH Part 2: efficacy and safety of risdiplam (RG7916) in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA) (1260). Neurology 2020;94:1260.","DOI":"10.1212\/WNL.94.15_supplement.1260"},{"key":"10.1007\/s13311-020-01004-3_bib15","doi-asserted-by":"crossref","unstructured":"Swoboda KJ, Prior TW, Scott CB , et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol 2005;57:704\u2013712.","DOI":"10.1002\/ana.20473"},{"key":"10.1007\/s13311-020-01004-3_bib16","doi-asserted-by":"crossref","unstructured":"Talbot K, Tizzano EF. The clinical landscape for SMA in a new therapeutic era. Gene Ther 2017;24:529\u2013533.","DOI":"10.1038\/gt.2017.52"},{"key":"10.1007\/s13311-020-01004-3_bib17","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/jpet.114.222224","article-title":"The small-molecule fast skeletal troponin activator, CK-2127107, improves exercise tolerance in a rat model of heart failure","volume":"353","author":"Hwee","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1007\/s13311-020-01004-3_bib18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/mus.26017","article-title":"CK-2127107 amplifies skeletal muscle response to nerve activation in humans","volume":"57","author":"Andrews","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-020-01004-3_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients","volume":"17","author":"O'Hagen","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-020-01004-3_bib20","doi-asserted-by":"crossref","unstructured":"Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. Muscle Nerve 2017;55:869\u2013874.","DOI":"10.1002\/mus.25430"},{"key":"10.1007\/s13311-020-01004-3_bib21","doi-asserted-by":"crossref","unstructured":"Dunaway Young S, Montes J, Kramer SS, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve 2016;54:836\u2013842.","DOI":"10.1002\/mus.25120"},{"key":"10.1007\/s13311-020-01004-3_bib22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mus.24153","article-title":"Performance of the timed \"up & go\" test in spinal muscular atrophy","volume":"50","author":"Dunaway","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-020-01004-3_bib23","doi-asserted-by":"crossref","first-page":"e1206","DOI":"10.1212\/WNL.0000000000006241","article-title":"Patient Reported Impact of Symptoms in Spinal Muscular Atrophy (PRISM-SMA)","volume":"91","author":"Mongiovi","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-020-01004-3_bib24","doi-asserted-by":"crossref","unstructured":"Shefner J, Andrews J, Genge A, et al. Update of FORTITUDE-ALS: a phase 2, double-blind, randomized, placebo-controlled, study to evaluate efficacy, safety and tolerability of reldesemtiv in patients with amyotrophic lateral sclerosis (S5.002). Neurology 2019;92:S5.002.","DOI":"10.1212\/WNL.92.15_supplement.S5.002"},{"key":"10.1007\/s13311-020-01004-3_bib25","doi-asserted-by":"crossref","unstructured":"Shefner JM, Wolff AA, Meng L, et al. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2016;17:426\u2013435.","DOI":"10.3109\/21678421.2016.1148169"},{"key":"10.1007\/s13311-020-01004-3_bib26","doi-asserted-by":"crossref","unstructured":"Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 2015;51:157\u2013167.","DOI":"10.1002\/mus.24497"},{"key":"10.1007\/s13311-020-01004-3_bib27","doi-asserted-by":"crossref","unstructured":"Ramsey D, Scoto M, Mayhew A, et al. Revised Hammersmith Scale for spinal muscular atrophy: a SMA specific clinical outcome assessment tool. PLoS One 2017;12:e0172346.","DOI":"10.1371\/journal.pone.0172346"},{"key":"10.1007\/s13311-020-01004-3_bib28","doi-asserted-by":"crossref","unstructured":"B\u00e9rard C, Payan C, Hodgkinson I, Fermanian J, MFM Collaborative Study Group. A motor function measure for neuromuscular diseases. Construction and validation study. Neuromuscul Disord 2005;15:463\u2013470.","DOI":"10.1016\/j.nmd.2005.03.004"},{"key":"10.1007\/s13311-020-01004-3_bib29","doi-asserted-by":"crossref","unstructured":"Vuillerot C, Payan C, Iwaz J, Ecochard R, B\u00e9rard C, MFM Spinal Muscular Atrophy Study Group. Responsiveness of the motor function measure in patients with spinal muscular atrophy. Arch Phys Med Rehabil 2013;94:1555\u20131561.","DOI":"10.1016\/j.apmr.2013.01.014"},{"key":"10.1007\/s13311-020-01004-3_bib30","doi-asserted-by":"crossref","unstructured":"Chabanon A, Seferian AM, Daron A, et al. Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS One 2018;13:e0201004.","DOI":"10.1371\/journal.pone.0201004"}],"updated-by":[{"DOI":"10.1007\/s13311-021-01120-8","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000}}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-01004-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-020-01004-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923011522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-01004-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T11:34:51Z","timestamp":1704713691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923011522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1878747923011522"],"URL":"https:\/\/doi.org\/10.1007\/s13311-020-01004-3","relation":{"erratum":[{"id-type":"doi","id":"10.1007\/s13311-021-01120-8","asserted-by":"object"}]},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-020-01004-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01120-8","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}